UPDATED May 14, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GTHX | US$4.69 | 9.3% | 69.3% | US$243.1m | US$8.50 | PS2.9x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
HHR | AU$0.007 | 0% | -73.1% | AU$19.7m | n/a | PE6.7x | E86.3% | n/a | Energy | ||
CRNA | kr2.02 | -9.4% | -89.1% | kr16.4m | kr12.00 | PS133.2x | E92.9% | n/a | Pharmaceuticals & Biotech | ||
ACTD | US$7.79 | -24.2% | -21.2% | US$303.0m | US$17.00 | PE-25.3x | E85.2% | n/a | Diversified Financials | ||
CDX | AU$0.054 | 5.9% | -78.4% | AU$15.9m | n/a | PS1.1x | E114.3% | n/a | Healthcare | ||
MTVFR | €0.018 | 3.5% | 15.8% | €3.4m | n/a | PS1x | E58.5% | 0% | Media | ||
ZWIPE | kr0.53 | -19.1% | -86.5% | kr52.8m | kr2.00 | PS25.2x | E73.3% | n/a | Tech | ||
MIST | US$1.73 | 1.8% | -56.9% | US$107.9m | US$10.25 | PB2.7x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
ALACT | €0.84 | 0% | -86.4% | €11.0m | €1.00 | PB30x | E81.5% | n/a | Pharmaceuticals & Biotech | ||
2GI | €3.00 | 0% | -70.3% | €12.6m | n/a | PB0.2x | E76.2% | 0% | Real Estate Management and Development | ||
AZ | US$0.44 | 14.5% | -77.3% | US$21.3m | US$18.00 | PS2x | E75.4% | n/a | Capital Goods | ||
ACR | AU$0.061 | -4.7% | 24.5% | AU$17.7m | n/a | PS1.6x | E115.3% | 0% | Pharmaceuticals & Biotech | ||
XBRANE | kr0.21 | 12.9% | -99.7% | kr328.8m | n/a | PS1.4x | E93.7% | n/a | Pharmaceuticals & Biotech | ||
CLBIO | kr10.10 | 0.5% | -35.9% | kr217.1m | kr29.00 | PS7x | E114.8% | n/a | Pharmaceuticals & Biotech | ||
ALPHE | €2.00 | 2.6% | -53.6% | €14.4m | €5.80 | PS4.6x | E78.8% | n/a | Pharmaceuticals & Biotech | ||
SONM | US$0.50 | -13.3% | -53.9% | US$25.1m | US$2.00 | PB1x | E139.9% | n/a | Tech | ||
PBH | AU$0.44 | -7.4% | -69.3% | AU$143.2m | n/a | PB1x | E116.0% | n/a | Consumer Services | ||
SAR | UK£0.42 | 72.2% | -65.9% | UK£44.6m | UK£1.76 | PB107x | E117.2% | n/a | Pharmaceuticals & Biotech | ||
OCUP | US$1.70 | -12.4% | -65.2% | US$43.0m | US$19.33 | PS2.3x | E51.0% | n/a | Pharmaceuticals & Biotech | ||
1086 | HK$0.64 | -5.9% | 4.9% | HK$1.1b | n/a | PE5.2x | E21.8% | 0% | Consumer Durables | ||
ZYNE | US$1.30 | 4.0% | 96.1% | US$65.6m | US$1.26 | PB2.3x | E67.2% | n/a | Pharmaceuticals & Biotech | ||
CALTX | kr122.70 | 9.6% | 18.0% | kr6.6b | kr208.00 | PS5.5x | E49.9% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$4.82 | -6.6% | -1.4% | US$200.9m | US$19.00 | PS7.3x | E65.3% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.43 | -3.2% | 62.0% | US$282.6m | US$11.33 | PB1.6x | E60.0% | n/a | Pharmaceuticals & Biotech |